Display options
Cite
Arellano J, González JM, Qian Y, et al. Physician preferences for bone metastasis drug therapy in Canada. Curr Oncol. 2015;22(5):e342-8doi: 10.3747/co.22.2380.
Arellano, J., González, J. M., Qian, Y., Habib, M., Mohamed, A. F., Gatta, F., Hauber, A. B., Posner, J., Califaretti, N., & Chow, E. (2015). Physician preferences for bone metastasis drug therapy in Canada. Current oncology (Toronto, Ont.), 22(5), e342-8. https://doi.org/10.3747/co.22.2380
Arellano, J, et al. "Physician preferences for bone metastasis drug therapy in Canada." Current oncology (Toronto, Ont.) vol. 22,5 (2015): e342-8. doi: https://doi.org/10.3747/co.22.2380
Arellano J, González JM, Qian Y, Habib M, Mohamed AF, Gatta F, Hauber AB, Posner J, Califaretti N, Chow E. Physician preferences for bone metastasis drug therapy in Canada. Curr Oncol. 2015 Oct;22(5):e342-8. doi: 10.3747/co.22.2380. PMID: 26628874; PMCID: PMC4608407.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2015 Oct;22(5):e342-8. doi: 10.3747/co.22.2380.

Physician preferences for bone metastasis drug therapy in Canada.

Current oncology (Toronto, Ont.)

J Arellano, J M González, Y Qian, M Habib, A F Mohamed, F Gatta, A B Hauber, J Posner, N Califaretti, E Chow

Affiliations

  1. Amgen, Thousand Oaks, CA, U.S.A.;
  2. RTI Health Solutions, Research Triangle Park, NC, U.S.A.;
  3. Amgen Canada, Toronto, ON;
  4. Amgen Europe, Zug, Switzerland;
  5. Grand River Regional Cancer Centre, Waterloo, ON;
  6. Sunnybrook Health Sciences Centre, Toronto, ON.

PMID: 26628874 PMCID: PMC4608407 DOI: 10.3747/co.22.2380

Abstract

BACKGROUND: Currently in Canada, several bone-targeted agents (btas) with varying characteristics are available for the prevention of skeletal-related events (sres) in patients with bone metastasis secondary to solid tumours. In the present study, we evaluated the preferences of physicians in Canada for the various attributes of the available btas.

METHODS: Physicians treating patients with bone metastasis from solid tumours were invited to complete an online discrete-choice experiment. Respondents were asked to choose between pairs of hypothetical medications for virtual patients. Each hypothetical medication was described based on predefined key attributes: time until first sre, time until worsening of pain, medication-related annual risk of osteonecrosis of the jaw (onj), medication-related annual risk of renal impairment, and mode of administration. A random-parameters logit model was used to analyze the choices between hypothetical medications and thus infer physician preferences for medication attributes.

RESULTS: Responses from the 200 physicians who completed the discrete-choice experiment suggested that months until first sre, risk of renal impairment, and months until worsening of pain were considered the most important attributes affecting choice of bta. The annual risk of onj was considered the least important attribute.

CONCLUSIONS: When making treatment decisions about the choice of bta for patients with bone metastasis from solid tumours, delaying sres and worsening of pain, and reducing the risk of renal impairment are primary considerations for physicians in Canada.

Keywords: Bone metastases; bone-targeted agents; conjoint analysis; discrete-choice experiments; physician preferences; skeletal-related events

References

  1. Oncologist. 2004;9 Suppl 4:14-27 - PubMed
  2. Oncology. 2004;67(5-6):390-6 - PubMed
  3. Clin Oncol (R Coll Radiol). 2006 Feb;18(1):67-9 - PubMed
  4. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s - PubMed
  5. Am J Manag Care. 2008 May;14(5):317-22 - PubMed
  6. Ther Clin Risk Manag. 2008 Feb;4(1):261-8 - PubMed
  7. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):193-7 - PubMed
  8. Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1501-10 - PubMed
  9. Lung Cancer. 2010 Jan;67(1):4-11 - PubMed
  10. J Clin Oncol. 2010 Dec 10;28(35):5132-9 - PubMed
  11. Lancet. 2011 Mar 5;377(9768):813-22 - PubMed
  12. Value Health. 2011 Jun;14(4):403-13 - PubMed
  13. Ann Oncol. 2012 May;23(5):1341-7 - PubMed
  14. Health Econ. 2012 Feb;21(2):145-72 - PubMed
  15. Patient. 2008 Dec 1;1(4):273-82 - PubMed
  16. Patient. 2010 Dec 1;3(4):249-56 - PubMed
  17. Can J Surg. 2012 Apr;55(2):95-8 - PubMed
  18. Eur J Cancer. 2012 Nov;48(16):3082-92 - PubMed
  19. Eur Rev Med Pharmacol Sci. 2012 Nov;16(12):1741-7 - PubMed
  20. Osteoarthritis Cartilage. 2013 Feb;21(2):289-97 - PubMed
  21. Value Health. 2013 Jan-Feb;16(1):3-13 - PubMed
  22. N Engl J Med. 2013 Jul 18;369(3):213-23 - PubMed
  23. Support Care Cancer. 2014 Mar;22(3):679-87 - PubMed
  24. Value Health. 2015 Jan;18(1):78-83 - PubMed
  25. Value Health. 2014 Nov;17(7):A570 - PubMed
  26. Cancer. 1997 Oct 15;80(8 Suppl):1588-94 - PubMed

Publication Types